Xilio Therapeutics, Inc.
NCM: XLOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Xilio Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get XLO Z-Score →About Xilio Therapeutics, Inc.
Healthcare
Biotechnology
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Xilio Therapeutics, Inc. demonstrates a profit margin of -80.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 693.9% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -132.5%, which indicates that capital utilization is currently under pressure.
At a current price of $8.51, XLO currently sits at the 20th percentile of its 52-week range (Range: $6.47 - $16.52).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$49.21M
Trailing P/E
--
Forward P/E
-14.67
Beta (5Y)
-0.12
52W High
$16.52
52W Low
$6.47
Avg Volume
39K
Day High
Day Low